Science Advisory Board features BTEC work on gene therapy projects

Published October 21, 2020

Caroline M. Smith-Moore
Caroline M. Smith-Moore
BTEC Assistant Director, Analytical

In an article published Oct. 16, 2020, the Science Advisory Board features BTEC’s efforts to develop novel analytical methodology specifically designed for adeno-associated viral vectors (AAVs). “New methods could improve AAV quality for viral vector manufacturing” explains that “[r]ecombinant AAVs are commonly used as viral vectors in gene therapies to deliver genetic materials into target cells. The manufacturing of these vectors requires extensive knowledge of methods to generate and purify AAVs.”

The article discusses the work Caroline Smith-Moore, BTEC assistant director, Analytical, is engaging in as part of a grant funded by NIIMBL, the National Institute for Innovation in Manufacturing Biopharmaceuticals. The project, entitled “Expanding AAV Process and Characterization Analytical Technologies,” began earlier this year and is expected to conclude in 2021. Project activities involve developing analytical methods to characterize AAVs, so analytical tools can be applied to manufacturing for the production of high-quality, desirable viral vectors.

BTEC's professional development courses and other projects related to gene therapy are also mentioned in the article. The latter include methods to increase AAV titers and downstream purification processes to separate empty and full capsids via ion exchange chromatography.

The Science Advisory Board, established in 1997, is an expert network of over 40,000 scientists immersed in biological research, drug discovery, and biopharmaceutical production.